الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 74 |  |  |
| | | from | 74 | | |
Abstract
Psoriasis is a chronic inflammatory papulo-squamous skin disorder. It is a lifelong ailment with exacerbations and remissions associated with significant comorbidities. It has a worldwide distribution affecting about 1%–3% of the population and is characterized clinically by well-demarcated erythematous plaques covered with silvery-white scales. These features are explained by epidermal hyperplasia and dilated superficial blood vessels. The pathogenesis of psoriasis includes hyper-proliferation of keratinocytes with abnormal differentiation along with inflammatory infiltration of T-cells in epidermis and dermis. Due to the variable clinical presentation in different types and stages, histopathological examination remains the gold standard for establishing the diagnosis. The histologic spectrum of psoriasis is well established, but with the administration of therapy, the cardinal histopathological features also change along with clinical improvement. Very few studies are documented in the literature which evaluates the response of psoriatic lesions histopathologically on treatment. Gordon et al. studied the dynamics of psoriatic lesions on treatment. They concluded that on giving treatment Munro micro-abscesses, exocytosis, and parakeratosis disappear with the reappearance of stratum granulosum and orthokeratosis. Acanthosis and papillomatosis also decrease while the diameter of blood vessels reduces slowly. Psoriasis is an autoimmune inflammatory skin disease. In the past several decades, phototherapy has been widely used to treat stable psoriatic lesions, including trunk, scalp, arms and legs, and partial nail psoriasis. A variety of light/ lasers with different mechanisms of action have been developed for psoriasis including ultraviolet B, psoralen ultraviolet A, pulsed dye laser, photodynamic therapy, intense pulsed light, light-emitting diodes, and so on. Squamous cell carcinoma antigen belongs to the ovalbumin– serpin family and is a known tumor marker. Expression of squamous cell carcinoma antigen is up-regulated in the serum and skin of patients with psoriasis. The evaluation of psoriasis is usually carried out through the estimation of the Psoriasis Area Severity Index score. However, the Psoriasis Area Severity Index score is not truly quantitative and varies among clinicians. In recent years, the treatment options for psoriasis have expanded because several biologics have been developed. Therefore, it is desirable to develop a new serum biomarker for psoriasis to evaluate disease activity and manage patient treatment. The squamous cell carcinoma antigen belongs to the ovalbumin–serpin family and has been widely used as a tumor marker, particularly for squamous cell carcinoma.
The aim of the study was to determine serum levels of squamous cell carcinoma, Antigen in patients with psoriasis and to evaluate if those levels are related to disease severity or response to treatment.
This was a case-control study that was conducted on Patients selected from the Outpatient Clinic of Dermatology, Venereology & Andrology department of Menoufiya University Hospitals in the period from the first of August 2018 to the end of February 2020; the study was conducted on 40 patients suffering from Psoriasis (group A). In addition to 40 apparently healthy individuals of matched age and sex as a control group (group B).